BioVie Inc.

#Parkinson's Disease #Alzheimer's Disease #Liver Disease #Neurodegeneration

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease and long COVID, as well as advanced liver disease.

Company Info

Sector:Biotechnology

Headquarters:Newton, Massachusetts, USA

Founded:2013

Website:bioviepharma.com/

Upcoming Milestones & Key Dates

August 2026

Corporate

Live investor webinar on SUNRISE-PD topline results

Q4 2026

Clinical

Next clinical milestones for bezisterim programs

Clinical Development Pipeline

Bezisterim (NE3107)

Target: Inflammatory/insulin-resistance pathway

Early Parkinson's disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Bezisterim (NE3107)

Target: Inflammatory/insulin-resistance pathway

Alzheimer's disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

BIV201

Target: Vasopressin receptor agonist

Advanced liver disease / ascites

Preclinical

Phase 1

Phase 2

Phase 3

Approved

BioVie shares halve on murky Parkinson’s disease readout ↗

BioVie shares halve on murky Parkinson’s disease readout

Leadership Team

Cuong Do

President and Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →